Effects of nirmatrelvir/ritonavir (Paxlovid) on the nervous system: analysis on adverse events released by FDA
Authors:
- 27 February 2025
- journal article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 25 (4) , 669-676
Abstract
Nirmatrelvir/ritonavir, commonly known as Paxlovid, is one of the main drugs used to treat COVID-19. Neurological disorders are among the adverse drug reactions (ADRs) linked to Paxlovid, yet comprehensive data-mining studies based on real-world neurological adverse events induced by Paxlovid are lacking. It is an observational study, to reduce the risk of bias affected by COVID-19 disease, our study included only patients with COVID-19 disease. In this case, disproportionate analysis is performed using the Report Odds Ratio (ROR) and its 95% Confidence Interval (CI). We screened and compared all medications associated with COVID-19 (N = 439) and found that 22 of these were linked to neurological adverse reactions. Paxlovid was associated with a threefold greater number of neurological adverse events compared to all other drugs combined (N = 11,792), with a strong signal value (ROR = 2.27). Compared to all other COVID-19-related drugs, Paxlovid has the highest number and stronger signal value for neurologic-related adverse reactions. Clinicians should pay special attention to female patients taking Paxlovid within the first 30 days, monitoring for symptoms such as dysgeusia, ageusia, headache, and anosmia. In addition, headache and anosmia are not uncommon occurrences as mentioned in the instructions and should be noted.Keywords
This publication has 48 references indexed in Scilit:
- ACE2 Receptor‐Targeted Inhaled Nanoemulsions Inhibit SARS‐CoV‐2 and Attenuate Inflammatory ResponsesAdvanced Materials, 2024
- Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysisJournal of Medical Virology, 2023
- Postmarketing Reporting of Paxlovid‐Related Dysgeusia: A Real‐World Pharmacovigilance StudyOtolaryngology–Head and Neck Surgery, 2023
- Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysisJournal of Medical Virology, 2023
- COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribedEuropean Journal of Clinical Pharmacology, 2022
- Identification of Drug Interaction Adverse Events in Patients With COVID-19JAMA Network Open, 2022
- Neurological manifestations in patients with COVID‐19: A systematic review and meta‐analysisJournal of Clinical Laboratory Analysis, 2022
- Nirmatrelvir Plus Ritonavir: First ApprovalDrugs, 2022
- SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like propertiesBrain, Behavior, and Immunity, 2021
- Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, ChinaJAMA Neurology, 2020